Aerie Pharmaceuticals, Inc.

Symbol: AERI

NASDAQ

15.25

USD

Market price today

  • -8.8838

    P/E Ratio

  • 0.2019

    PEG Ratio

  • 753.62M

    MRK Cap

  • 0.00%

    DIV Yield

Aerie Pharmaceuticals, Inc. (AERI) Stock Price & Analysis

Shares Outstanding

49.39M

Gross Profit Margin

0.82%

Operating Profit Margin

-0.77%

Net Profit Margin

-0.83%

Return on Assets

-0.22%

Return on Equity

0.57%

Return on Capital Employed

-0.32%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO:Dr. Vicente Anido
Full-time employees:376
City:Durham
Address:4301 Emperor Blvd Ste 400
IPO:2013-10-25
CIK:0001337553

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

General Outlook

In simple terms, Aerie Pharmaceuticals, Inc. has 49.391 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.824% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.773%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.827%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.219% return, is a testament to Aerie Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Aerie Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.572%. Furthermore, the proficiency of Aerie Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.317% return on capital employed.

Stock Prices

Aerie Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $15.23, while its low point bottomed out at $15.22. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Aerie Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing AERI liquidity ratios reveals its financial health of the firm. The current ratio of 227.11% gauges short-term asset coverage for liabilities. The quick ratio (184.76%) assesses immediate liquidity, while the cash ratio (40.57%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio227.11%
Quick Ratio184.76%
Cash Ratio40.57%

Profitability Ratios

AERI profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -81.85% underscores its earnings before tax deductions. The effective tax rate stands at -1.03%, revealing its tax efficiency. The net income per EBT, 101.03%, and the EBT per EBIT, 105.82%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -77.34%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-81.85%
Effective Tax Rate-1.03%
Net Income per EBT101.03%
EBT per EBIT105.82%
EBIT per Revenue-77.34%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.27, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding185
Days of Inventory Outstanding978
Operating Cycle1045.09
Days of Payables Outstanding190
Cash Conversion Cycle323
Receivables Turnover1.34
Payables Turnover1.93
Inventory Turnover0.37
Fixed Asset Turnover1.40
Asset Turnover0.26

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.78, and free cash flow per share, 0.70, depict cash generation on a per-share basis. The cash per share value, 3.61, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.38, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.78
Free Cash Flow per Share0.70
Cash per Share3.61
Operating Cash Flow Sales Ratio0.38
Free Cash Flow to Operating Cash Flow Ratio0.90
Cash Flow Coverage Ratio0.11
Short Term Coverage Ratio7.65
Capital Expenditure Coverage Ratio9.86
Dividend Paid and Capex Coverage Ratio9.86

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 89.72%, highlights its total liabilities relative to assets. With a debt-equity ratio of -2.06, we discern the balance between debt and equity financing. The long-term debt to capitalization, 197.53%, and total debt to capitalization, 194.79%, ratios shed light on its capital structure. An interest coverage of -17.18 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio89.72%
Debt Equity Ratio-2.06
Long Term Debt to Capitalization197.53%
Total Debt to Capitalization194.79%
Interest Coverage-17.18
Cash Flow to Debt Ratio0.11
Company Equity Multiplier-2.29

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 4.19, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.61, reflects the portion of profit attributed to each share. The book value per share, -0.37, represents the net asset value distributed per share, while the tangible book value per share, -0.37, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share4.19
Net Income Per Share-1.61
Book Value Per Share-0.37
Tangible Book Value Per Share-0.37
Shareholders Equity Per Share-0.37
Interest Debt Per Share6.25
Capex Per Share-0.07

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 548,737,148.92, captures the company's total value, considering both debt and equity. Income quality, 1.33, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value548,737,148.92
Income Quality1.33
Research and Development to Revenue39.06%
Capex to Operating Cash Flow3.32%
Capex to Revenue-1.70%
Capex to Depreciation-8.78%
Stock-Based Compensation to Revenue15.21%
Graham Number3.69
Return on Tangible Assets-17.34%
Graham Net Net-3.66
Working Capital230,659,000
Tangible Asset Value-17,333,000
Net Current Asset Value-93,074,000
Invested Capital-15
Average Receivables107,425,000
Average Payables8,555,500
Average Inventory33,734,500
Days Sales Outstanding299
Days Payables Outstanding113
Days of Inventory On Hand549
ROIC-13.40%
ROE4.32%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -4.45, and the price to book ratio, -4.45, reflect the market's valuation relative to the company's book value.

cards.indicatorcards.value
Price Book Value Ratio-4.45
Price to Book Ratio-4.45
Price Cash Flow Ratio19.56
Price Earnings to Growth Ratio0.20
Enterprise Value Multiple4.26
Price Fair Value-4.45
Price to Operating Cash Flow Ratio19.56
Price to Tangible Book Ratio-18.77
Enterprise Value to Sales2.83
Enterprise Value Over EBITDA-70.23
EV to Operating Cash Flow-5.53
Earnings Yield-23.00%
Free Cash Flow Yield-31.49%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Aerie Pharmaceuticals, Inc. (AERI) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -8.884 in 2024.

What is the ticker symbol of Aerie Pharmaceuticals, Inc. stock?

The ticker symbol of Aerie Pharmaceuticals, Inc. stock is AERI.

What is company IPO date?

IPO date of Aerie Pharmaceuticals, Inc. is 2013-10-25.

What is company current share price?

Current share price is 15.250 USD.

What is stock market cap today?

The market cap of stock today is 753615360.000.

What is PEG ratio in 2024?

The current 0.202 is 0.202 in 2024.

What is the number of employees in 2024?

In 2024 the company has 376.